Investment Thesis
ImageneBio exhibits fundamental business failure indicators: essentially zero revenue (800K), massive operating losses (-5668.6% net margin), and severely negative free cash flow (-48.3M annually). While the balance sheet provides approximately 2 years of cash runway, the complete absence of revenue generation and unsustainable burn rate indicate the company has not achieved commercial viability or demonstrated a clear path to profitability.
Strengths
- Strong balance sheet with 94.5M in cash reserves and zero debt (0.00x debt/equity ratio)
- Excellent liquidity position (12.49x current ratio) provides operational runway for continued development
- Net loss improvement trend with 13.4% YoY reduction in losses, indicating some operational progress
Risks
- Unsustainable cash burn rate of 47.8M annually with only ~2 year runway remaining at current burn
- Essentially pre-revenue business (800K revenue) with no meaningful commercial traction
- Massive operating losses (-5668.6% net margin) with no visible path to profitability in current financial data
- Negative operating cash flow (-47.8M) demonstrates the business model is not self-sustaining
- Zero year-over-year revenue growth indicates stagnation in core business activity
Key Metrics to Watch
- Quarterly cash burn rate trend and remaining cash runway sustainability
- Revenue growth acceleration and path to positive operating cash flow
- Operating cash flow improvement trajectory and timeline to breakeven
Financial Metrics
Revenue
800.0K
Net Income
-45.3M
EPS (Diluted)
$-9.64
Free Cash Flow
-48.3M
Total Assets
153.0M
Cash
94.5M
Profitability Ratios
Gross Margin
N/A
Operating Margin
-6,056.4%
Net Margin
-5,668.6%
ROE
-34.1%
ROA
-29.6%
FCF Margin
-6,032.3%
Balance Sheet & Liquidity
Current Ratio
12.49x
Quick Ratio
12.49x
Debt/Equity
0.00x
Debt/Assets
13.0%
Interest Coverage
N/A
Long-term Debt
N/A
Disclaimer: This analysis is generated by AI based on publicly available SEC EDGAR filings.
It does not include stock price data and should not be considered financial advice.
All fundamental data is sourced from SEC public domain filings.
Always conduct your own research before making investment decisions.
Data Source: SEC EDGAR |
Analysis Date: 2026-04-11T17:54:25.042643 |
Data as of: 2025-12-31 |
Powered by Claude AI